Tags

Type your tag names separated by a space and hit enter

Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Clin Endocrinol (Oxf) 2014; 80(6):905-10CE

Abstract

OBJECTIVE

Selenium is effective in improving quality of life and reducing the progression of active Graves' orbitopathy. The effect of correcting relative selenium deficiency on improving Graves' orbitopathy is unknown, as baseline selenium levels have not previously been measured. The study aims to determine whether serum selenium levels are reduced in patients with Graves' disease with orbitopathy (GO) compared with without orbitopathy (GD).

DESIGN

A prospective, case-control study performed between 2009 and 2012 at endocrine and ophthalmology clinics in Australia.

PATIENTS

A total of 198 patients with Graves' disease participated in the study: 101 with Graves' orbitopathy and 97 without Graves' orbitopathy.

MEASUREMENTS

Serum selenium levels in both groups.

RESULTS

Mean serum selenium levels were significantly lower in GO (1·10 ± 0·18 μm) than in GD (1·19 ± 0·20 μm) (P = 0·001). Mean selenium levels appeared to decrease in parallel with increasing severity of GO; selenium level was 1·19 ± 0·20 μm in GD, 1·10 ± 0·19 μm in moderate-to-severe GO and 1·09 ± 0·17 μm in sight-threatening GO (P = 0·003). Serum selenium levels remained significantly lower in GO after adjusting for age, smoking status, thyroidectomy, radioactive iodine treatment and residential location.

CONCLUSION

Serum selenium levels are lower in patients with GO compared with GD in an Australian study population with marginal selenium status. Relative selenium deficiency may be an independent risk factor for orbitopathy in patients with Graves' disease.

Authors+Show Affiliations

NorthWest Academic Centre, The University of Melbourne, Western Health, St. Albans, Australia; Orbital Plastics and Lacrimal Unit, The Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24372054

Citation

Khong, Jwu Jin, et al. "Serum Selenium Status in Graves' Disease With and Without Orbitopathy: a Case-control Study." Clinical Endocrinology, vol. 80, no. 6, 2014, pp. 905-10.
Khong JJ, Goldstein RF, Sanders KM, et al. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):905-10.
Khong, J. J., Goldstein, R. F., Sanders, K. M., Schneider, H., Pope, J., Burdon, K. P., ... Ebeling, P. R. (2014). Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Clinical Endocrinology, 80(6), pp. 905-10. doi:10.1111/cen.12392.
Khong JJ, et al. Serum Selenium Status in Graves' Disease With and Without Orbitopathy: a Case-control Study. Clin Endocrinol (Oxf). 2014;80(6):905-10. PubMed PMID: 24372054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. AU - Khong,Jwu Jin, AU - Goldstein,Rebecca F, AU - Sanders,Kerrie M, AU - Schneider,Hans, AU - Pope,Jeffrey, AU - Burdon,Kathryn P, AU - Craig,Jamie E, AU - Ebeling,Peter R, Y1 - 2014/01/30/ PY - 2013/08/18/received PY - 2013/09/08/revised PY - 2013/12/11/revised PY - 2013/12/15/accepted PY - 2013/12/31/entrez PY - 2014/1/1/pubmed PY - 2014/12/17/medline SP - 905 EP - 10 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 80 IS - 6 N2 - OBJECTIVE: Selenium is effective in improving quality of life and reducing the progression of active Graves' orbitopathy. The effect of correcting relative selenium deficiency on improving Graves' orbitopathy is unknown, as baseline selenium levels have not previously been measured. The study aims to determine whether serum selenium levels are reduced in patients with Graves' disease with orbitopathy (GO) compared with without orbitopathy (GD). DESIGN: A prospective, case-control study performed between 2009 and 2012 at endocrine and ophthalmology clinics in Australia. PATIENTS: A total of 198 patients with Graves' disease participated in the study: 101 with Graves' orbitopathy and 97 without Graves' orbitopathy. MEASUREMENTS: Serum selenium levels in both groups. RESULTS: Mean serum selenium levels were significantly lower in GO (1·10 ± 0·18 μm) than in GD (1·19 ± 0·20 μm) (P = 0·001). Mean selenium levels appeared to decrease in parallel with increasing severity of GO; selenium level was 1·19 ± 0·20 μm in GD, 1·10 ± 0·19 μm in moderate-to-severe GO and 1·09 ± 0·17 μm in sight-threatening GO (P = 0·003). Serum selenium levels remained significantly lower in GO after adjusting for age, smoking status, thyroidectomy, radioactive iodine treatment and residential location. CONCLUSION: Serum selenium levels are lower in patients with GO compared with GD in an Australian study population with marginal selenium status. Relative selenium deficiency may be an independent risk factor for orbitopathy in patients with Graves' disease. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/24372054/Serum_selenium_status_in_Graves'_disease_with_and_without_orbitopathy:_a_case_control_study_ L2 - https://doi.org/10.1111/cen.12392 DB - PRIME DP - Unbound Medicine ER -